Drugs / Brenipatide
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07476118 | Mar 2026 → Feb 2027 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07202871 | Nov 2025 → Sep 2026 overdue | — | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07165002 | Oct 2025 → Nov 2026 expected | liver disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07165015 | Sep 2025 → Apr 2026 | end stage renal failure, impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06606106 | Sep 2024 → Nov 2026 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04648865 | Dec 2020 → Jun 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07759245 | Aug 2026 → May 2028 expected | chronic obstructive pulmonary disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07545759 | May 2026 → Sep 2027 expected | diarrheal disease, irritable bowel syndrome | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07545772 | Apr 2026 → Jul 2027 expected | constipation disorder, irritable bowel syndrome | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07420283 | Feb 2026 → Mar 2028 expected | substance-related disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07410507 | Feb 2026 → Nov 2027 expected | schizophrenia | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07286175 | Nov 2025 → Nov 2027 expected | bipolar disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07223840 | Nov 2025 → Feb 2027 expected | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07219173 | Oct 2025 → Apr 2028 expected | asthma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07775300 | Aug 2026 → Dec 2028 expected | major depressive disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07412756 | Feb 2026 → Feb 2028 expected | major depressive disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07219953 | Oct 2025 → Apr 2028 expected | alcohol-related disorders | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07219966 | Oct 2025 → Apr 2028 expected | alcohol-related disorders | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brenipatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07759245 ↗ |
| Known as | LY3537031 | “A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity” NCT07476118 ↗ |
| Route | Subcutaneous | “Administered SC.” NCT04648865 ↗ |